$ABBV News

What Are Wall Street Analysts' Target Price for AbbVie Stock?

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $285

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and ...

AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

AbbVie Inc. Q2 2026 Earnings Call Summary

Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today

AbbVie Q2 Earnings Call Highlights

AbbVie Beats but Cuts Guidance on $10.9 Billion Acquisition

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares fall on earnings miss and weak guidance

AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results

Conference Call: AbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est